Omnicell, Inc. (NASDAQ:OMCL) Given Average Recommendation of “Hold” by Brokerages

Shares of Omnicell, Inc. (NASDAQ:OMCL) have been assigned a consensus recommendation of “Hold” from the seven analysts that are covering the company, Marketbeat.com reports. Four analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $41.33.

A number of equities research analysts have recently commented on the stock. Barclays raised shares of Omnicell from an “underweight” rating to an “equal weight” rating and raised their price objective for the stock from $26.00 to $39.00 in a research note on Friday, August 2nd. Benchmark restated a “buy” rating and set a $48.00 price target on shares of Omnicell in a research report on Wednesday, October 9th. Bank of America lifted their price objective on shares of Omnicell from $34.00 to $44.00 and gave the company a “buy” rating in a report on Friday, August 2nd. Wells Fargo & Company increased their target price on shares of Omnicell from $30.00 to $41.00 and gave the stock an “equal weight” rating in a research note on Monday, October 14th. Finally, JPMorgan Chase & Co. lifted their price target on Omnicell from $26.00 to $37.00 and gave the company a “neutral” rating in a research note on Friday, August 23rd.

Institutional Trading of Omnicell

Several institutional investors have recently modified their holdings of OMCL. Everence Capital Management Inc. acquired a new position in shares of Omnicell during the 3rd quarter worth about $249,000. Accurate Wealth Management LLC increased its stake in Omnicell by 14.8% during the 3rd quarter. Accurate Wealth Management LLC now owns 21,260 shares of the company’s stock worth $901,000 after buying an additional 2,746 shares in the last quarter. Creative Planning raised its holdings in shares of Omnicell by 23.1% during the third quarter. Creative Planning now owns 11,667 shares of the company’s stock valued at $509,000 after acquiring an additional 2,188 shares during the last quarter. Diversified Trust Co lifted its position in shares of Omnicell by 43.0% in the third quarter. Diversified Trust Co now owns 21,966 shares of the company’s stock valued at $958,000 after acquiring an additional 6,602 shares in the last quarter. Finally, GAMMA Investing LLC boosted its stake in shares of Omnicell by 78.4% in the third quarter. GAMMA Investing LLC now owns 1,258 shares of the company’s stock worth $55,000 after acquiring an additional 553 shares during the last quarter. Institutional investors and hedge funds own 97.70% of the company’s stock.

Omnicell Trading Down 1.5 %

Shares of Omnicell stock opened at $40.47 on Tuesday. Omnicell has a 1 year low of $25.12 and a 1 year high of $45.84. The company has a debt-to-equity ratio of 0.47, a current ratio of 2.45 and a quick ratio of 2.22. The stock has a market cap of $1.86 billion, a PE ratio of -87.98, a price-to-earnings-growth ratio of 47.11 and a beta of 0.83. The firm has a fifty day moving average price of $43.22 and a 200 day moving average price of $34.42.

Omnicell (NASDAQ:OMCL) last issued its quarterly earnings data on Thursday, August 1st. The company reported $0.51 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.14 by $0.37. The business had revenue of $276.80 million during the quarter, compared to analysts’ expectations of $254.41 million. Omnicell had a positive return on equity of 2.52% and a negative net margin of 1.92%. The company’s revenue for the quarter was down 7.4% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.29 EPS. Equities research analysts predict that Omnicell will post 0.64 earnings per share for the current year.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.